首页> 美国卫生研究院文献>Case Reports in Hematology >Hip Replacement Surgery in 14-Year-Old Girl with Factor V Deficiency: Haemostatic Treatment and Thromboprophylaxis
【2h】

Hip Replacement Surgery in 14-Year-Old Girl with Factor V Deficiency: Haemostatic Treatment and Thromboprophylaxis

机译:具有因子V缺乏症的14岁女孩的髋关节置换手术:止血治疗和血栓预防

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Factor V (FV) is a pivotal coagulation factor present in plasma and platelets. It plays an essential role in secondary haemostasis acting as a cofactor in the prothrombinase complex, catalysing the conversion of prothrombin to thrombin. There is little evidence on the management of mayor orthopaedic surgery in paediatric or adolescents subjects with this coagulopathy and almost no information about thromboprophylaxis in these situations. We report a case of a hip replacement in a 14-year-old girl with moderate FV deficiency (0.07 IU mL−1). As haemostatic replacement, inactivated fresh frozen plasma (FFP) was transfused at doses of 600 mL (15 mL kg−1, 45 kg weight) 2 hours before surgery and then sequential FFP infusions of 250 mL (7 mL kg−1) every 12 hours for 7 days. Plasma factor VIII, von Willebrand factor antigen, and von Willebrand ristocetin cofactor were monitored to avoid supranormal levels. Since the patient was sexually mature (Marshall and Tanner stage 5) with the hormone replacement therapy, she was immobilized and the surgery was considered as a high thrombotic risk. Thus, low molecular weight heparin was administered at doses of intermediate risk (Enoxaparin 20 mg daily, by weight) after finishing the daily infusion of plasma: 24 hours and during the 7 days after intervention. No tranexamic acid was used. No haemorrhagic or thrombotic adverse event was described.
机译:因子V(FV)是血浆和血小板中存在的关键凝血因子。它在凝血酶原复合物中作为辅助因子的继发止血中起重要作用,催化凝血酶原转化为凝血酶。在患有这种凝血病的小儿或青少年中,很少有关于市长整形外科手术管理的证据,并且在这些情况下几乎没有关于预防血栓的信息。我们报告了一名中度FV缺乏(0.07 IU mL -1 )的14岁女孩的髋关节置换病例。作为止血替代品,在手术前2小时以600µmL(15µmL·kgkg -1 ,体重45µkg重量)的剂量输注灭活的新鲜冷冻血浆(FFP),然后连续FFP输注250µmL(7)。每12小时一次(mL kg -1 ),共7天。监测血浆VIII因子,von Willebrand因子抗原和von Willebrand ristocetin辅因子以避免超常水平。由于患者已通过激素替代疗法达到性成熟状态(Marshall和Tanner的第5期),因此已被固定,因此手术被认为具有高血栓形成风险。因此,在完成每日血浆输注后:24小时和干预后的7天内,以中等风险剂量(每天依诺肝素20毫克,按重量计)给予低分子量肝素。不使用氨甲环酸。没有描述出血性或血栓性不良事件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号